Effect of eye pigmentation on transscleral drug delivery

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 1, 2008, Pages 333-341

  Cheruvu, Narayan P S ^a   Amrite, Aniruddha C ^a   Kompella, Uday B ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; MELANIN; SODIUM HYDROXIDE; CYCLOOXYGENASE 2 INHIBITOR; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; PYRAZOLE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BROWN NORWAY RAT; CHOROID; CONTROLLED STUDY; CORNEA; DRUG ADMINISTRATION ROUTE; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RAT; RETINA; SCLERA; SPRAGUE DAWLEY RAT; SUSTAINED DRUG RELEASE; TRANSCLERAL DRUG ADMINISTRATION; VITREOUS BODY; ANIMAL; BIOAVAILABILITY; COMPARATIVE STUDY; DRUG EFFECT; EYE COLOR; MALE; METABOLISM;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHOROID; CYCLOOXYGENASE 2 INHIBITORS; DRUG CARRIERS; EYE COLOR; LACTIC ACID; MALE; MELANINS; PIGMENT EPITHELIUM OF EYE; POLYGLYCOLIC ACID; POLYMERS; PYRAZOLES; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; RETINA; SCLERA; SULFONAMIDES; VITREOUS BODY;

EID: 38749096430     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0214     Document Type: Article

References (40)

1. Marra M, Gukasyan HJ, Raghava S, Kompella UB. 2nd Ophthalmic Drug Development and Delivery Summit San Diego, CA, 19-20 September 2006. Expert Opin Drug Deliv. 2007;4:77-85.
2. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99-114.
3. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47:S41-S52.
4. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002;21:145-151.
5. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52:37-48.
6. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
7. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47:1149-1160.
8. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005;511:191-198.
9. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44:1192-1201.
10. Van Quill KR, Dioguardi PK, Tong CT, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology. 2005;112:1151-1158.
11. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
12. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006;47:4513-4522.
13. Leblanc B, Jezequel S, Davies T, Hanton G, Taradach C. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol. 1998;28:124-132.
14. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004;21:1797-1804.
15. Schoenwald RD, Tandon V, Wurster DE, Barfknecht CF. Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino-4-methyl- delta2-1,3,4,-thiadiazolin e-2-sulfonamide. Eur J Pharm Biopharm. 1998;46:39-50.
16. Donatien P, Jeffery G. Correlation between rod photoreceptor numbers and levels of ocular pigmentation. Invest Ophthalmol Vis Sci. 2002;43:1198-1203.
17. Nofsinger JB, Forest SE, Eibest LM, Gold KA, Simon JD. Probing the building blocks of eumelanins using scanning electron microscopy. Pigment Cell Res. 2000;13:179-184.
18. Abrahamsson T, Bostrom S, Brautigam J, Lagerstrom PO, Regardh CG, Vauqelin G. Binding of the beta-blockers timolol and H 216/44 to ocular melanin. Exp Eye Res. 1988;47:565-577.
19. Ono C, Tanaka M. Binding characteristics of fluoroquinolones to synthetic levodopa melanin. J Pharm Pharmacol. 2003;55:1127-1133.
20. Meredith P, Sarna T. The physical and chemical properties of eumelanin. Pigment Cell Res. 2006;19:572-594.
21. Ono C, Yamada M, Tanaka M. Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. J Pharm Pharmacol. 2003;55:1647-1654.
22. Salazar-Bookaman MM, Wainer I, Patil PN. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol. 1994;10:217-239.
23. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos. 2002;30:421-429.
24. Acheampong AA, Small D, Baumgarten V, Welty D, Tang-Liu D. Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther. 2002;18:325-337.
25. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1959;2:478-480.
26. Tamilvanan S, Abdulrazik M, Benita S. Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study. J Drug Target. 2006;14:670-679.
27. Marrakchi-Benjaafar S, Cochereau I, D'Hermies F, Pocidalo JJ. Tolerability, kinetics, and efficacy of subconjunctival pefloxacin in pigmented rabbits. Antimicrob Agents Chemother. 1995;39:834-838.
28. Barza M, Kane A, Baum JL. Regional differences in ocular concentration of gentamicin after subconjunctival and retrobulbar injection in the rabbit. Am J Ophthalmol. 1977;83:407-413.
29. Tsuji A, Tamai I, Sasaki K. Intraocular penetration kinetics of prednisolone after subconjunctival injection. Ophthalmic Res. 1988;20:31-43.
30. Jenkins CD, Tuft SJ, Sheraidah G, McHugh DA, Buckley RA. Comparative intraocular penetration of topical and injected cefuroxime. Br J Ophthalmol. 1996;80:685-688.
31. Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci. 1996;37:613-618.
32. Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128:192-197.
33. Hemady RK, Chu W, Foster CS. Intraocular penetration of ketoconazole in rabbits. Cornea. 1992;11:329-333.
34. Baum JL, Barza M, Shushan D, Weinstein L. Concentration of gentamicin in experimental corneal ulcers: topical vs subconjunctival therapy. Arch Ophthalmol. 1974;92:315-317.
35. Lim JI, Maguire AM, John G, Mohler MA, Fiscella RG. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery. Ophthalmology. 1993;100:373-376.
36. Sasaki H, Kashiwagi S, Mukai T, et al. Drug absorption behavior after periocular injections. Biol Pharm Bull. 1999;22:956-960.
37. Sasaki H, Kashiwagi S, Mukai T, et al. Topical delivery system of ophthalmic drugs by periocular injection with viscous solution. Biol Pharm Bull. 1999;22:961-965.
38. Wine NA, Gornall AG, Basu PK. The ocular uptake of subconjunctivally injected C14 hydrocortisone. Pt. 1. Time and major route of penetration in a normal eye. Am J Ophthalmol. 1964;58:362-366.
39. Kim TW, Lindsey JD, Aihara M, Anthony TL, Weinreb RN. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest Ophthalmol Vis Sci. 2002;43:1809-1816.
40. Menon IA, Wakeham DC, Persad SD, Avaria M, Trope GE, Basu PK. Quantitative determination of the melanin contents in ocular tissues from human blue and brown eyes. J Ocul Pharmacol. 1992;8:35-42.